A plethora of showstopping clinical trial data readouts are being met with refreshed excitement, enthusiasm and R&D investment for adenosine-pathway targets, one of the most validated and established oncology pathways. As such, the inaugural Adenosine-Pathway Targeted Cancer Immunotherapy Summit has arrived as the definitive conference dedicated to optimizing efficacy of adenosine-pathway targeted drugs, overcoming challenges of resistance and immunosuppression and supercharging therapeutics into the clinic. Uniting experts in adenosine, immune checkpoint, tumor microenvironment, immune-oncology and second-generation IO, don’t miss your chance to investigate adenosine signaling in the context of the hypoxic tumor microenvironment to inform clinical advances, leverage biomarkers to evaluate disease and identify patient responders for Adenosine-Pathway therapeutics. Join fellow pioneers in the field to explore preclinical model landscapes and gain a deeper understanding of the rationale of combination therapies to enhance treatment potency & efficacy.
